---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113811"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:02:07.166105+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA lifts clinical hold on Atara's EBVALLO program; Type A meeting granted

## Summary
- FDA lifted clinical hold on EBVALLO (tabelecleucel) IND applications, allowing resumption of Phase 3 ALLELE and Phase 2 label-expansion studies.
- FDA granted a Type A meeting to discuss path forward for BLA resubmission after January 2025 CRL citing GMP issues at third-party facility.
- Strategic option evaluation temporarily paused pending FDA clarity on BLA resubmission timing.
- Clinical hold directly linked to GMP compliance issues identified during pre-license inspection; resolved with supplemental finished drug product data.

## SEC filing metadata
- accession: 0001193125-25-113811
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/0001193125-25-113811-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113811
- JSON: https://secwatch.observer/filing/0001193125-25-113811.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113811.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.